News and Trends 14 Nov 2022 Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Priothera’s Mocravimod improves survival for patients with hematological malignancies Priothera, a biotechnology company developing its S1P receptor modulator compound Mocravimod, has announced that positive data from a clinical trial reinforces the potential for the drug to improve survival outcomes for patients with hematological malignancies. The study has been evaluating Mocramivod in allogeneic hematopoietic cell transplantation patients and was published in journal Transplantation and Cellular […] November 14, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 EpiEndo gets regulatory approval for first patient study of first non-antibiotic macrolide EpiEndo Pharmaceuticals, a clinical-stage biopharma company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to begin a phase 2a clinical trial. The trial will be with lead molecule EP395 in COPD (chronic obstructive pulmonary disease) patients, an orally available macrolide or ‘Barriolide,’ with reduced antimicrobial resistance potential. It aims to address the unmet […] November 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022 PACT Pharma reports data from CRISPR cancer study PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients’ immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT Pharma’s platforms, demonstrated early proof-of-concept that a patient’s immune system can be reprogrammed […] November 11, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 SOTIO reveal potential treatment for adults with solid tumors at SITC meeting SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 10 Nov 2022 Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Ascentage Pharma gets Chinese approval for solid tumor study Ascentage Pharma says its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration (NMPA) to enter a phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearance for the study in the […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2022 PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […] November 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2022 Wyss Center’s ABILITY system to improve quality of life for people with severe paralysis The Wyss Center for Bio and Neuroengineering has shared the latest signals recorded by its fully plantable ABILITY brain computer interface (BCI) at a Society for Neuroscience meeting. ABILITY is designed to improve quality of life and independence for people with severe paralysis and demonstrates safety and efficacy in pre-clinial trials. New details of the […] November 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Vir Biotech presents new data for functional cure of chronic Hep B virus Vir Biotechnology, Inc. today (November 8) announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting was delivered in two oral presentations, both of which were selected […] November 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Nov 2022 ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […] November 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 MedinCell’s partner AIC registers trial for drug for total knee replacement pain A partner of MedinCell, Arthritis Innovation Corporation (AIC), has registered a phase 3 trial to look into an alternative drug to deal with pain after total knee replacement (TKR). Arthritis Innovation Corporation conducts and finances all development activities of the drug F14, or mdc-CWM, being trialed. It was registered with the safety and efficacy study […] November 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email